Headache News and Research

Latest Headache News and Research

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience, Inc., a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic M, has "robust efficacy".

22 May 2013

New study identifies risk factors for rupture or bleeding in children with arachnoid cysts

Arachnoid cysts are a common type of brain lesion that is usually harmless, but with a risk of rupture or bleeding. A new study identifies risk factors for rupture or bleeding in children with "incidentally" detected arachnoid cysts, reports the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

22 May 2013

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

UCB today announced data from a double-blind, placebo-controlled study that found that Neupro (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure elevations associated with periodic limb movements during sleep and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome/Willis-Ekbom disease.

18 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Sigma-Tau Pharmaceuticals recognized as a rare disease pioneer

Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30th anniversary celebration of The National Organization for Rare Disorders.

15 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1 in 10 stroke patients suffer chronic and debilitating pain, typically described as sharp, stabbing or burning. It's called central poststroke pain syndrome (CPSP). It was first described more than 100 years ago, and it is treatable with medications and magnetic or electrical stimulation of the brain.

9 May 2013

High school football players are unconcerned over sports-related concussions

Many high school football players say it's OK to play with a concussion even though they know they are at risk of serious injury, according to a study to be presented Monday, May 6, at the Pediatric Academic Societies (PAS) annual meeting in Washington, DC.

6 May 2013

Gene mutation associated with rare sleep disorder also contributes to debilitating migraines

A gene mutation associated with a rare sleep disorder surprisingly also contributes to debilitating migraines, a new discovery that could change the treatment of migraines by allowing development of drugs specifically designed to treat the chronic headaches.

3 May 2013

Study identifies the vector that transmitted malaria from apes to humans

In 2010, a study revealed that the main agent of malaria in humans, called Plasmodium falciparum, arose from the gorilla. Today, the vector which transmitted the parasite from apes to humans has just been identified.

3 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Five sudden signs and symptoms of stroke

Stroke is the fourth-leading cause of death in the United States. Each year an estimated 795,000 people in this country experience a stroke. That's approximately the equivalent of every man, woman and child living in Anaheim and Long Beach combined.

3 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

Researchers identify genetic mutation linked to a typical form of migraine

A research team led by a Howard Hughes Medical Institute investigator at the University of California, San Francisco has identified a genetic mutation that is strongly associated with a typical form of migraine.

2 May 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Headache News and Research

Latest Headache News and Research

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

New study identifies risk factors for rupture or bleeding in children with arachnoid cysts

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Sigma-Tau Pharmaceuticals recognized as a rare disease pioneer

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

High school football players are unconcerned over sports-related concussions

Gene mutation associated with rare sleep disorder also contributes to debilitating migraines

Study identifies the vector that transmitted malaria from apes to humans

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Five sudden signs and symptoms of stroke

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Researchers identify genetic mutation linked to a typical form of migraine

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in